分化好的甲状腺癌转移灶的^（131）I治疗

￣(131)I therapy of differentiated thyroid cancer metastases

对２５例分化好的甲状腺癌术后转移灶有摄取１３１Ｉ功能者进行了１３１Ｉ治疗．按不同转移部位给予不同量的１３１Ｉ，其一次剂量为３．７～７．４ＧＢｑ，累积剂量为３．７～２９．６ＧＢｑ，平均为９．４５ＧＢｑ．结果转移灶摄取１３１Ｉ功能完全消除者１２例（４８．０％），部分消除者８例（３２．０％），好转后复发者１例（４．０％）．无效或加重者４例（１６．０％），总有效率８４．０％．其中以颈部软组织转移者疗效最好，肺或肺与软组织转移者次之，骨或骨与软组织转移者最差．

Abstract patients with metastases from differentiated papillary,follicular and mixed thyroid cancer were treated with ￣(131)I after surgery.These patients all demonstrated some concentration or ￣(131)I within their metastatic foci,as seen by ￣(131)I whole body imaging.Single doses varying from 3.7～7.4GBq were used, depending on extent of the disease and the site(s) of involvement.Total doses of 3.7～29.6GBq,average 9.45GBq,were given for proven mctastases. The results showed that metastascs as a result of ￣(131)I concentration disappeared completely in 12 patients (48%),partly in 9 patients (36.0%) and responded poorly in 4 patients (16.0%) with a total effective rate of 84.0% (21/25).The effective rate was the highest for metastases in the cervical soft tissue,also high for metastases in the lung and the lowest for metastases in the bone.